Carregant...
Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience
BACKGROUND: Although giant cell tumors (GCTs) are benign, their aggressiveness and tendency to recur locally challenge the orthopaedic surgeon’s ability to perform joint-preserving intralesional surgery with an acceptably low risk of local recurrence. Denosumab has emerged as a possible medical trea...
Guardat en:
| Publicat a: | Clin Orthop Relat Res |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wolters Kluwer
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6259809/ https://ncbi.nlm.nih.gov/pubmed/30794215 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11999.0000000000000243 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|